The value of miR-510 in the prognosis and development of colon cancer

Hang, Junjie; Wei, Feifei; Yan, Zhiying; Zhang, Xianming; Xu, Kequn; Zhu, Yichao

doi:10.1515/med-2021-0251

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another nucleic acid therapeutic approach is to affect the expression level of microRNAs (miRNAs), as their aberrant expression mediates initiation, development, and progression of various cancers. 206 , 207 , 208 , 209 , 210 , 211 , 212 The downregulation of miRNA‐34a is observed in breast tumor and promoting its expression could be beneficial in impairing tumor progression. CS‐based nanocarriers can provide co‐delivery of DOX and miRNA‐34a in breast tumor suppression.…”

Section: Nanostructures Of Chitosan‐doxorubicinmentioning

confidence: 99%

“…205 Another nucleic acid therapeutic approach is to affect the expression level of microRNAs (miRNAs), as their aberrant expression mediates initiation, development, and progression of various cancers. [206][207][208][209][210][211][212] The downregulation of miRNA-34a is observed in breast tumor and promoting its expression could be beneficial in Furthermore, CS provides a site for conjugation to ligands to selectively target receptors overexpressed on tumor cells. 183,[186][187][188][189][190] These benefits advocate application of CS-based nano-scale delivery systems for DOX chemotherapy.…”

Section: Doxorubicin and Gene Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy

Ashrafizadeh

Hushmandi

Mirzaei

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

Green chemistry has been a growing multidisciplinary field in recent years showing great promise in biomedical applications, especially for cancer therapy. Chitosan (CS) is an abundant biopolymer derived from chitin and is present in insects and fungi. This polysaccharide has favorable characteristics, including biocompatibility, biodegradability, and ease of modification by enzymes and chemicals. CS‐based nanoparticles (CS‐NPs) have shown potential in the treatment of cancer and other diseases, affording targeted delivery and overcoming drug resistance. The current review emphasizes on the application of CS‐NPs for the delivery of a chemotherapeutic agent, doxorubicin (DOX), in cancer therapy as they promote internalization of DOX in cancer cells and prevent the activity of P‐glycoprotein (P‐gp) to reverse drug resistance. These nanoarchitectures can provide co‐delivery of DOX with antitumor agents such as curcumin and cisplatin to induce synergistic cancer therapy. Furthermore, co‐loading of DOX with siRNA, shRNA, and miRNA can suppress tumor progression and provide chemosensitivity. Various nanostructures, including lipid‐, carbon‐, polymeric‐ and metal‐based nanoparticles, are modifiable with CS for DOX delivery, while functionalization of CS‐NPs with ligands such as hyaluronic acid promotes selectivity toward tumor cells and prevents DOX resistance. The CS‐NPs demonstrate high encapsulation efficiency and due to protonation of amine groups of CS, pH‐sensitive release of DOX can occur. Furthermore, redox‐ and light‐responsive CS‐NPs have been prepared for DOX delivery in cancer treatment. Leveraging these characteristics and in view of the biocompatibility of CS‐NPs, we expect to soon see significant progress towards clinical translation.

show abstract

Section: Nanostructures Of Chitosan‐doxorubicinmentioning

confidence: 99%

Section: Doxorubicin and Gene Deliverymentioning

confidence: 99%

Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy

Ashrafizadeh

Hushmandi

Mirzaei

et al. 2022

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

lncRNA ELFN1-AS1 enhances the progression of colon cancer by targeting miR-4270 to upregulate AURKB

et al. 2022

View full text Add to dashboard Cite

The oncogenic role of lncRNA ELFN1-AS1 has been described in different cancers, including colon cancer (CC). However, how ELFN1-AS1 regulates CC malignancy remains unclear. In this study, ELFN1-AS1, AURKB, and miR-4270 expression levels in CC cells and tissues were determined using RT-qPCR and western blotting. CCK-8 and wound healing assays were also performed to analyze alterations in CC cell proliferation and migration. The expression of apoptosis-related proteins (Bax and Bcl-2) was determined via western blot analysis. RNA immunoprecipitation (RIP) assays coupled with luciferase reporter assays were employed to verify the relationship between miR-4270, ELFN1-AS1, and AURKB. An in vivo assay was performed using xenograft tumors in mice to detect the change of tumor growth. It was found that AURKB and ELFN1-AS1 expression was upregulated, whereas miR-4270 was downregulated in CC cells and tissues. ELFN1-AS1 silencing exhibited anti-proliferative, anti-migratory, and pro-apoptotic effects in CC cells. The tumor-suppressive effect of ELFN1-AS1 silencing was verified using in vivo assays. MiR-4270 was predicted to be a target of ELFN1-AS1 and AURKB as a target of miR-4270. Their interactions were further elucidated using luciferase reporter and RNA RIP assays. More importantly, treatment with a miR-4270 inhibitor not only rescued the tumor-suppressing effect of ELFN1-AS1 silencing but also abrogated the tumor suppressor functions of AURKB silencing in CC cells. Taken together, the ELFN1-AS1/miR-4270/AURKB axis facilitates CC tumorigenesis; therefore, targeting this axis might be a promising intervention in preventing CC progression.

show abstract

MicroRNA-510 mediated negative regulation of Caveolin-1 in fibroblasts promotes aggressive tumor growth

King,

Krisanits,

Guo

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

IntroductionIn the US, despite the recent decline in breast cancer deaths, a persistent mortality disparity exists between black and white women with breast cancer, with black women having a 41% higher death rate. Several studies are now reporting that racial disparities can exist independent of socioeconomic and standard of care issues, suggesting that biological factors may be involved. Caveolin-1 (Cav1) loss in the tumor stromal compartment is a novel clinical biomarker for predicting poor outcome in breast cancer including triple negative subtype, however the mechanism of Cav1 loss is unknown. We previously identified miR-510-5p as a novel oncomir and propose here that the high levels observed in patients is a novel mechanism leading to stromal Cav1 loss and worse outcomes.MethodsCav1 was identified as a direct target of miR-510-5p through luciferase, western blot and qPCR assays. Stromal cross talk between epithelial cells and fibroblasts was assessed in vitro using transwell co-culture assays and in vivo using xenograft assays.ResultsWe found that Cav1 is a direct target of miR-510-5p and that expression in fibroblasts results in an ‘activated’ phenotype. We propose that this could be important in the context of cancer disparities as we also observed increased levels of circulating miR-510-5p and reduced levels of stromal Cav1 in black women compared to white women with breast cancer. Finally, we observed a significant increase in tumor growth when tumor cells were co-injected with miR-510-5p expressing cancer associated fibroblasts in vivo.ConclusionWe propose that miR-510-5p mediated negative regulation of Cav1 in fibroblasts is a novel mechanism of aggressive tumor growth and may be a driver of breast cancer disparity.

show abstract

The value of miR-510 in the prognosis and development of colon cancer

Cited by 3 publications

References 31 publications

Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy

Chitosan‐based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy

lncRNA ELFN1-AS1 enhances the progression of colon cancer by targeting miR-4270 to upregulate AURKB

MicroRNA-510 mediated negative regulation of Caveolin-1 in fibroblasts promotes aggressive tumor growth

Contact Info

Product

Resources

About